NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义*

doi:10.3969/j.issn.1672-5069.2020.02.015

Abstract

Abstract: Objective The aim of this study was to investigate the changes of blood glycosylated hemoglobin(HbA1C) and thyroid hormone levels in patients with nonalcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM). Methods 50 patients with T2DM and 55 patients with NAFLD complicated byT2DM were recruited in the Department of Endocrinology in our hospital between April 2017 and March 2019, and all patients underwent somatology, serum liver and kidney function tests, blood lipids, HbA1C, fasting insulin (FINS), free triiodothyronine (FT3), free tetraiodothyronine(FT4) and thyroid stimulating hormone (TSH) were assayed. Results The body mass index (BMI) in patients with NAFLD complicated byT2DM was (28. 4±2.7) kg/m², significantly higher than [(24. 0±2.4) kg/m², P<0.05] in patients with T2DM, the waist circumference in patients with NAFLD and T2DM was (94.5±8.5) cm, significantly higher than(84.0_7.6) cm, P < 0.05)in patients with T2DM, and the hip circumference in patients with NAFLD complicated by T2DM was (97.1±8.0) cm, significantly higher than (89.7±7.2) cm, P<0.05) in T2DM patients;serum level of alanine aminotransferasein patients with NAFLD complicated by T2DM was (79.5±7.6) u/L, significantly higher than [(42.3±4.3) μ/L, P<0.05] in patients with T2DM, serum aspartate aminotransferase level in patients with NAFLD complicated by T2DM was (59.7±6.1) u/L, significantly higher than[(41.2±3.9) u/L, P<0.05] in patients with T2DM, and serum level of glutamyltranspeptidasein patients with NAFLD complicated byT2DM was (105.8±9.4) u/L, significantly higher than [(60.9±6.5) u/L, P<0.05] in patients with T2DM; blood triglyceride levelin patients with NAFLD complicated by T2DM was (4.2±1.7) mmol/L, significantly higher than [(2.4±0.9) mmol/L, P<0.05] in patients with T2DM, and blood level of fasting insulinin patients with NAFLD complicated by T2DM was (12.0±2.5) mU/L, significantly higher than [(9.1±1.8) mU/L, P<0.05] in patients with T2DM;serum level of thyroid stimulating hormone level in patients with NAFLD complicated byT2DM was (3.4±1.2) mU/L, significantly higher than [(1.9±0.8) mU/L, P<0.05] in patients with T2DM, while serum FT3 and FT4 levels in the two groups were not significantly different (P>0.05). Conclusion The BMI, serum liver function index, TG, FINS and TSH in patients with NAFLD complicated by T2DMchange greatly, significantly different as compared to in patients with T2DM,and clinicians should take these differences into consideration in clinical practice for early diagnosis and management.

Key words: Nonalcoholic fatty liver disease, Type 2 diabetes mellitus, Thyroid stimulating hormone, Fasting insulin, Glycosylated hemoglobin

Liu Jiguo, Dou Cuiyun , Cheng Guangling. Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM[J]. Journal of Practical Hepatology, 2020, 23(2): 207-210.

References

[1] Ahn SB, Jun DW, Kang BK, et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep, 2019, 9(1): 5688-5688.
[2] Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 2018, 14(2): 88-98.
[3] 宋娜, 刘晓燕, 刘畅, 等. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义. 实用肝脏病杂志, 2019, 22(1): 65-68.
[4] Miyake T, Yoshida S, Furukawa S, et al. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars), 2018, 13: 402-409.
[5] Demir F,Şmşek FS, Ansal Balc T. The role of pre-ablative stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio for predicting metastasis in thyroid cancer. Mol Imaging Radionucl Ther, 2019, 28(1): 21-26.
[6] Verma S, Leiter LA, Mazer CD, et al. Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use. Circulation, 2018, 138(15): 1605-1607.
[7] de Gracia Hahn D, Duret A, Mann JP. An agtr1 variant worsens nonalcoholic fatty liver disease and the metabolic syndrome. Am J Gastroenterol, 2019, 114(4): 556-559.
[8] Mansour-Ghanaei F, Pourmasoumi M, Hadi A, et al. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: a systematic review of randomized controlled trials. Integr Med Res, 2019, 22(1): 57-61.
[9] Schumacher-Petersen C, Christoffersen B, Kirk RK, et al. Experimental non-alcoholic steatohepatitis in Gttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes. J Transl Med, 2019, 17(1): 110-110.
[10] 崔清华, 陶红, 王晓玥, 等. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究. 实用肝脏病杂志, 2019, 22(1): 69-71.
[10] Rubie C, Zimmer J, Lammert F, et al. Microrna-496 and mechanistic target of rapamycin expression are associated with type 2 diabetes mellitus and obesity in elderly people. Ann Nutr Metab, 2019, 74(4): 279-286.
[11] Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2019, 9(3): e017995.
[12] Mullish BH, Forlano R, Abeles RD, et al. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease - authors' reply. Aliment Pharmacol Ther, 2019, 49(8): 1093-1094.
[13] Deng XL, Ma R, Zhu HX, et al. A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2017, 29(3): 297-301.
[14] van den Berg EH, Flores-Guerrero JL, Gruppen EG, et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched-chain amino acids. Nutrients, 2019, 11(3): 705-705.
[15] Mu W, Cheng XF, Liu Y, et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues. Front Pharmacol, 2019, 9(1): 1566-1566.
[16] 胡利勋, 杨建全. 快步走联合太极拳锻炼对高龄非酒精性脂肪性肝病合并高血压患者血压和肝功能的影响. 实用肝脏病杂志, 2015, 18(5): 508-511.
[17] 邵庆华, 郑盛, 杨涓, 等. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平变化研究. 实用肝脏病杂志, 2016, 19(2): 175-179.
[18] Hu Y, Chen J, Yang L, et al. The value of neck circumference (nc) as a predictor of non-alcoholic fatty liver disease (nafld). J Clin Transl Endocrinol, 2014, 1(4): 133-139.
[19] Bril F, Kadiyala S, Portillo Sanchez P, et al. Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes. J Investig Med, 2016, 64(1): 63-8.
[20] 阎劲松, 袁丹, 李东升. 影响2型糖尿病患者新发非酒精性脂肪肝相关因素分析. 实用肝脏病杂志, 2016, 19(2): 212-214.

Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Jiali, Li Li, Zhao Fei, et al. Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 167-170.
[2]	Ye Xiaoxian, Yang Li, Lei Li. Predictive value of serum glycosylated hemoglobin and IL-6levels on the risk of nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(2): 199-202.
[3]	Jia Chen, Zhang Tao, Wang Hao, et al. Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(2): 203-206.
[4]	Ren Guoliang, Li Liansheng, Liu Gang, et al. Improvement of insulin resistance, lipid profile and oxidative stress index by calorie restriction diet in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 219-222.
[5]	Chen Lili, Fu Maoxiong, Meng Xubiao, et al. Clinical value of fasting C-peptide in assessing the progression of liver fibrosis in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2020, 23(1): 38-41.
[6]	Mao Chongshan, Yin Hui, Xiao Erhui, et al. Effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(1): 50-53.
[7]	Luo Qingling, Zhou Yongjian, Tang Wenjuan, et al. Effects of fecal bacteria transplantation on microflora in rats with high-fat-induced liver steatosis [J]. Journal of Practical Hepatology, 2020, 23(1): 134-137.
[8]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[9]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[10]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[11]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[12]	Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.
[13]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[14]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[15]	Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.